Active Mitochondria, Unwelcome Cellular Consequences

Previous Science Note  

Mitochondrial function is generally evaluated using parameters such as oxygen consumption rate, membrane potential, ATP production, and reactive oxygen species (ROS). However, even when electron transport is maintained or enhanced, such changes do not necessarily contribute to normal cellular function. Recent studies have begun to reveal specific mechanisms by which alterations in mitochondrial electron transport support neurodegeneration or drug resistance in cancer cells.
In the first study, tau, a microtubule-associated protein known for its role in axonal transport, was found to promote reverse electron transport (RET) through Complex I. Excessive RET increased ROS production and lowered the NAD⁺/NADH ratio, creating a vicious cycle that contributed to neurodegeneration. In the second study, colorectal cancer cells that survived chemotherapy exhibited increased mitochondrial biogenesis and oxidative metabolism, which supported drug resistance. Inhibition of Complex I further increased sensitivity to chemotherapy.
These findings suggest that maintained or enhanced mitochondrial electron transport and respiration do not necessarily indicate a beneficial cellular state. In addition to measuring Complex I activity and oxygen consumption rate (OCR), combining assessments of ATP production, mitochondrial ROS, and the NAD⁺/NADH ratio with cellular outcomes such as viability and drug sensitivity is important for understanding how mitochondrial alterations contribute to neuronal damage and chemotherapy resistance.

Tau-induced mitochondrial reverse electron transport drives neurodegeneration
(Li et al., Neuron, 2026)

Summary
Tau pathology and mitochondrial dysfunction are both associated with neurodegenerative diseases, but how tau influences mitochondrial electron transport has remained unclear. In this study, the authors examined tau's role in regulating RET across human iPSC-derived neurons, Drosophila, and mouse models of tauopathy, and found that tau directly interacts with a Complex I protein to regulate RET. Enhanced RET was associated with increased mitochondrial ROS, a reduced NAD⁺/NADH ratio, and neuronal injury-related phenotypes. These findings identify a previously unrecognized mechanism linking abnormal tau, RET, and neurodegeneration.

Highlighted technique
To determine whether tau directly regulates reverse electron transport through Complex I, the authors compared RET- and FET-associated mitochondrial ROS production and NAD⁺/NADH status in isolated mitochondria. Tau localization, interaction with Complex I proteins, mitophagy-related markers, apoptosis-associated endpoints, and cell viability were examined to assess how RET-related metabolic changes are linked to neuronal injury.

In addition to measuring Complex I activity and OCR after mitochondrial fractionation, mitochondrial ROS and intracellular NAD⁺/NADH measurements may help characterize metabolic shifts associated with RET. 


Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer
(Moss et al., Nature Metabolism, 2026)

Summary
In this study, the authors evaluated mitochondrial abundance, Complex I activity, and oxidative metabolism in chemotherapy-surviving colorectal cancer cells, since the metabolic basis underlying their survival remained unclear. Surviving cells showed increased mitochondrial content, elevated Complex I activity, and enhanced oxidative metabolism, and Complex I inhibition restored chemotherapy sensitivity. These findings indicate that mitochondrial metabolic adaptation underlies chemotherapy resistance in colorectal cancer.

Highlighted technique
To characterize metabolic features of chemotherapy-surviving colorectal cancer cells, the authors assessed mitochondrial abundance, Complex I activity in isolated mitochondria, and mitochondrial respiration. Complex I inhibition was then used to assess whether mitochondrial metabolic changes were associated with chemotherapy sensitivity.

OCR and ATP measurements in living cells detect changes in mitochondrial respiration and energy metabolism. Combining these with Complex I activity assays after mitochondrial fractionation identifies whether such changes are driven specifically by Complex I.


 


Mitochondrial Related Activity Indicators (click to open/close)
Target Kit & Probes
Intact Mitochondria Fractionation IntactMito Fractionation Kit for Tissue
MitoComplex-I Activity Assay MitoComplex-I Activity Assay Kit
Oxygen consumption rate assay Extracellular OCR Plate Assay Kit
Mitochondrial superoxide detection MitoBright ROS Deep Red - Mitochondrial Superoxide Detection
Mitochondrial Staining MitoBright LT Green / Red / Deep Red
Mitochondrial membrane potential detection JC-1 MitoMP Detection Kit, MT-1 MitoMP Detection Kit
Intracellular ATP mesurement ATP Assay Kit-Luminescence
Cell proliferation/ cytotoxicity assay Cell Counting Kit-8 and Cytotoxicity LDH Assay Kit-WST
Apoptosis detection in multiple samples Annexin V Apoptosis Plate Assay Kit
Application Note I (click to open/close)
> Inhibition of Mitochondrial Electron Transport Chain

Antimycin stimulation of Jurkat cells was used to evaluate the changes in cellular state upon inhibition of the mitochondrial electron transport chain using a variety of indicators.

The results showed that inhibition of the electron transport chain resulted in (1) a decrease in mitochondrial membrane potential and (2) a decrease in OCR. In addition, (3) the NAD+/NADH ratio of the entire glycolytic pathway decreased due to increased metabolism of pyruvate to lactate to maintain the glycolytic pathway, (4) GSH depletion due to increased reactive oxygen species (ROS), and (6) increase in the NADP+/NADPH ratio due to decreased NADH required for glutathione biosynthesis were observed.

 

   

  

Application Note II (click to open/close)
> Activity Evaluation of Mitochondria Fractionated from Mouse Brain

 

Mitochondria were isolated from mouse brain tissue, and oxygen consumption rate (OCR), mitochondrial membrane potential (MMP), and Complex I activity were measured.

The results showed that the addition of succinate, a substrate that activates Complex II of the electron transport chain, increased both OCR and MMP. In contrast, FCCP treatment reduced MMP, indicating that intact mitochondria were successfully fractionated.
Furthermore, in the Complex I activity assay, a decrease in activity was observed following treatment with rotenone, a Complex I inhibitor.

<Product used>
    Mitochondrial Fractionation: 
 IntactMito Fractionation Kit for Tissue (Code: MT17)
 OCR measurement: 
 Extracellular OCR Plate Assay Kit (Code: E297)
 MMP detection: 
 JC-1 MitoMP Detection Kit (Code: MT09)
 Complex I activity assay:  
 MitoComplex- I Activity Assay Kit (Code: MT18)

<Experimental Conditions>
OCR Measurement   
    Amount of mitochondria: 50 μg/well (as protein levels)
    Succinate: 10 mmol/l
MMP Detection  
    Amount of mitochondria: 50 μg/well (as protein levels)
    Succinate: 10 mmol/l,   FCCP: 4 μmol/l
Complex I Activity Assay  
    Amount of mitochondria: 20 μg/well (as protein levels)
       Rotenone: 10 μmol/l

Product Classification

Product Classification